Testpage/Main 1: Difference between revisions
< Testpage
Jacki Buros (talk | contribs) No edit summary |
Jacki Buros (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{|style="border-spacing:8px; margin:0px -8px;" | {|style="border-spacing:8px; margin:0px -8px;" | ||
|class="MainPageBG" style="width:35%; border:1px solid #cef2e0; background:#f5fffa; vertical-align:top; color:#000;"| | |class="MainPageBG" style="width:35%; border:1px solid #cef2e0; background:#f5fffa; vertical-align:top; color:#000;"| | ||
| Line 5: | Line 4: | ||
! <h2 style="margin:0; background:#cedff2; font-size:120%; font-weight:bold; border:1px solid #a3b0bf; text-align:left; color:#000; padding:0.2em 0.4em;">WikiDoc News: Today in Medicine</h2> | ! <h2 style="margin:0; background:#cedff2; font-size:120%; font-weight:bold; border:1px solid #a3b0bf; text-align:left; color:#000; padding:0.2em 0.4em;">WikiDoc News: Today in Medicine</h2> | ||
|- | |- | ||
|style="color:#000; font-size: | |style="color:#000; font-size:95%;"| | ||
June 17, 2009: [[Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet|'''''Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet''''']] | June 17, 2009: [[Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet|'''''Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet''''']] | ||
The ATLAS ACS-TIMI 46 Study Group investigators reported today in ''The Lancet'' that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51). | :The ATLAS ACS-TIMI 46 Study Group investigators reported today in ''The Lancet'' that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51). | ||
{{GNews}} | {{GNews}} | ||
|- | |- | ||
|} | |} | ||
Revision as of 20:26, 22 June 2009
|